| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Ulrich Dirnagl | Q27870042 |
| P2860 | cites work | Systematic evaluation and comparison of statistical tests for publication bias | Q81455289 |
| Epidemiology and reporting of randomised trials published in PubMed journals | Q81584040 | ||
| Statins and stroke | Q81623503 | ||
| Why most published research findings are false | Q21092395 | ||
| Sifting the evidence-what's wrong with significance tests? | Q24524896 | ||
| Where is the evidence that animal research benefits humans? | Q24601393 | ||
| Publication bias in situ | Q24801473 | ||
| Tackling publication bias in clinical trial reporting. PLoS announces the launch of a new online journal | Q24812106 | ||
| Pathobiology of ischaemic stroke: an integrated view | Q28141682 | ||
| The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials | Q28185637 | ||
| Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research | Q28285027 | ||
| Tissue plasminogen activator for acute ischemic stroke | Q29619377 | ||
| Advances in neuroprotection trials | Q30624519 | ||
| Prehospital and in-hospital delays in acute stroke care | Q30652175 | ||
| Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. | Q30882783 | ||
| The therapeutic value of nimodipine in experimental focal cerebral ischemia. Neurological outcome and histopathological findings | Q69065405 | ||
| Effect sizes and p values: what should be reported and what should be replicated? | Q71640170 | ||
| Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks | Q73187556 | ||
| For ischemic brain damage, is preclinical evidence of neuroprotection by presynaptic blockade of glutamate release enough? | Q73735489 | ||
| Selective reporting biases in cancer prognostic factor studies | Q80395257 | ||
| Publication bias and journals as policemen | Q80872161 | ||
| Magnetic resonance imaging in experimental models of brain disorders | Q30885751 | ||
| Pooling of animal experimental data reveals influence of study design and publication bias | Q30918723 | ||
| Mechanisms underlying recovery of motor function after stroke | Q30978384 | ||
| What has diffusion imaging in animals told us about diffusion imaging in patients with ischaemic stroke? | Q30985886 | ||
| Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. | Q30992275 | ||
| Recovery and rehabilitation in stroke: stem cells | Q31117918 | ||
| Magnetic resonance imaging criteria for thrombolysis in acute cerebral infarct. | Q33210344 | ||
| Recommendations for standards regarding preclinical neuroprotective and restorative drug development | Q33785562 | ||
| Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis | Q33812064 | ||
| Why do neuroprotective drugs work in animals but not humans? | Q33887012 | ||
| Nervous system reorganization following injury | Q34130225 | ||
| Calcium antagonists for ischemic stroke: a systematic review | Q34130838 | ||
| Knockout mice: simple solutions to the problems of genetic background and flanking genes | Q34134816 | ||
| Practical aspects of experimental design in animal research | Q34155516 | ||
| Emergency medicine animal research: does use of randomization and blinding affect the results? | Q34202311 | ||
| Recommendations for clinical trial evaluation of acute stroke therapies. | Q34300670 | ||
| Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors | Q34389549 | ||
| Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review | Q34392812 | ||
| The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct? | Q34481206 | ||
| Does animal experimentation inform human healthcare? Observations from a systematic review of international animal experiments on fluid resuscitation | Q34540924 | ||
| Cell transplantation for stroke | Q34805823 | ||
| Systematic reviews of animal experiments | Q34871813 | ||
| Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective | Q34941187 | ||
| Animal models of focal and global cerebral ischemia | Q35090269 | ||
| Models of focal cerebral ischemia in the nonhuman primate | Q35090273 | ||
| Mechanisms, challenges and opportunities in stroke | Q35120144 | ||
| Ischemic tolerance and endogenous neuroprotection | Q35126696 | ||
| Design of future acute-stroke treatment trials | Q35172350 | ||
| Treatment of neural injury with marrow stromal cells | Q35172499 | ||
| Why have so many drugs with stellar results in laboratory stroke models failed in clinical trials? A theory based on allometric relationships | Q35174559 | ||
| Animal models of stroke: do they have value for discovering neuroprotective agents? | Q35198028 | ||
| Meta-analysis of the effects of endothelin receptor blockade on survival in experimental heart failure | Q35570391 | ||
| Gene expression changes after focal stroke, traumatic brain and spinal cord injuries | Q35587077 | ||
| The ischemic penumbra: identification, evolution and treatment concepts | Q35615678 | ||
| Thrombolysis: from the experimental findings to the clinical practice | Q35615748 | ||
| Neuroprotection in cerebral ischaemia: facts and fancies--the need for new approaches | Q35615757 | ||
| What have genetically engineered mice taught us about ischemic injury? | Q35699533 | ||
| Transplantation for stroke | Q35772691 | ||
| Lost in translation: taking neuroprotection from animal models to clinical trials. | Q35832807 | ||
| Pathophysiology of stroke: lessons from animal models | Q35956294 | ||
| Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke | Q35992930 | ||
| Exciting, radical, suicidal: how brain cells die after stroke | Q36002053 | ||
| Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke | Q36036681 | ||
| Neuroprotection for ischemic stroke: two decades of success and failure | Q36045217 | ||
| Cell therapy for stroke | Q36045372 | ||
| A systematic review of nitric oxide donors and L-arginine in experimental stroke; effects on infarct size and cerebral blood flow. | Q36083655 | ||
| Nitric oxide synthase inhibitors in experimental ischemic stroke and their effects on infarct size and cerebral blood flow: a systematic review. | Q36182005 | ||
| Central nervous system injury-induced immune deficiency syndrome | Q36257627 | ||
| Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia | Q36260781 | ||
| Design and statistical methods in studies using animal models of development | Q36359731 | ||
| Empirical assessment of effect of publication bias on meta-analyses. | Q38630464 | ||
| Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia | Q39133981 | ||
| Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression | Q40397153 | ||
| The past is the future: innovative designs in acute stroke therapy trials | Q40424628 | ||
| Stroke units: the next 10 years | Q40523795 | ||
| Knockout mice | Q40966754 | ||
| Transgenic and knockout mice in the study of neurodegenerative diseases | Q41143203 | ||
| Does effect of a neuroprotective agent on volume of experimental animal cerebral infarct predict effect of the agent on clinical outcome in human stroke? | Q41643160 | ||
| Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models. | Q41710325 | ||
| Ten year follow-up of a randomised controlled trial of care in a stroke rehabilitation unit | Q42130289 | ||
| Surveying the literature from animal experiments: systematic review and meta-analysis are important contributions | Q43068321 | ||
| Stroke unit treatment. 10-year follow-up | Q43579028 | ||
| Local Cerebral Blood Flow and Vascular Reactivity in a Chronic Stable Stroke in Baboons | Q48442721 | ||
| Can statistics cause brain damage? | Q48740885 | ||
| Use of animal models has not contributed to development of acute stroke therapies: pro. | Q48788244 | ||
| Use of animal models has not contributed to development of acute stroke therapies: con. | Q48788262 | ||
| Pre- and post-treatment with MK-801 but not pretreatment alone reduces neocortical damage after focal cerebral ischemia in the rat. | Q48897841 | ||
| Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. | Q48960167 | ||
| Clinical trials in acute stroke: why have they not been successful? | Q51501002 | ||
| Using knockout and transgenic mice to study neurophysiology and behavior. | Q51990334 | ||
| Principles: the need for better experimental design. | Q52012369 | ||
| The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. | Q52373114 | ||
| Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. | Q52940189 | ||
| Stroke neuroimaging. | Q53659622 | ||
| Tissue plasminogen activator reduces neurological damage after cerebral embolism. | Q53986915 | ||
| Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) | Q55063586 | ||
| Ischemia and Stroke | Q56969358 | ||
| Hypothermia but not the N-methyl-D-aspartate antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia | Q68927696 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 1465-1478 | |
| P577 | publication date | 2006-03-08 | |
| P1433 | published in | Journal of Cerebral Blood Flow & Metabolism | Q14663525 |
| P1476 | title | Bench to bedside: the quest for quality in experimental stroke research | |
| P478 | volume | 26 |
| Q27323219 | A Comparative Study of Variables Influencing Ischemic Injury in the Longa and Koizumi Methods of Intraluminal Filament Middle Cerebral Artery Occlusion in Mice |
| Q24289291 | A combined pre-clinical meta-analysis and randomized confirmatory trial approach to improve data validity for therapeutic target validation |
| Q28658665 | A concerted appeal for international cooperation in preclinical stroke research |
| Q35866886 | A critical appraisal of experimental intracerebral hemorrhage research |
| Q30838086 | A microarray study of gene and protein regulation in human and rat brain following middle cerebral artery occlusion |
| Q48425614 | A reproducible and translatable model of focal ischemia in the visual cortex of infant and adult marmoset monkeys |
| Q36640055 | ATF4 is an oxidative stress-inducible, prodeath transcription factor in neurons in vitro and in vivo |
| Q48174485 | Allopregnanolone protects against dopamine-induced striatal damage after in vitro ischaemia via interaction at GABA A receptors |
| Q41189585 | An alternative surgical approach reduces variability following filament induction of experimental stroke in mice. |
| Q37489766 | An endovascular canine middle cerebral artery occlusion model for the study of leptomeningeal collateral recruitment |
| Q48123797 | An improved automated method to quantitate infarct volume in triphenyltetrazolium stained rat brain sections |
| Q37780478 | Animal models of the cancer anorexia–cachexia syndrome |
| Q48412887 | Antigen dependently activated cluster of differentiation 8-positive T cells cause perforin-mediated neurotoxicity in experimental stroke. |
| Q34901610 | Are Underlying Assumptions of Current Animal Models of Human Stroke Correct: from STAIRs to High Hurdles? |
| Q39628293 | Autonomic reactions and peri-interventional alterations in body weight as potential supplementary outcome parameters for thromboembolic stroke in rats |
| Q37597099 | Blocking of platelet glycoprotein receptor Ib reduces "thrombo-inflammation" in mice with acute ischemic stroke. |
| Q37447090 | Bone marrow-derived mononuclear cells do not exert acute neuroprotection after stroke in spontaneously hypertensive rats |
| Q37459051 | CD36: a multi-modal target for acute stroke therapy |
| Q39392693 | COU254, a specific 3-carboxamide-coumarin inhibitor of coagulation factor XII, does not protect mice from acute ischemic stroke |
| Q21563449 | Can animal models of disease reliably inform human studies? |
| Q37418272 | Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought |
| Q34262937 | Changes in stroke research productivity: A global perspective |
| Q50525029 | Chronic methamphetamine exposure prior to middle cerebral artery occlusion increases infarct volume and worsens cognitive injury in Male mice. |
| Q46620582 | Control of cerebral ischemia with magnetic nanoparticles |
| Q35356980 | Cortical neurogenesis in adult rats after ischemic brain injury: most new neurons fail to mature |
| Q27321143 | Deficiency in serine protease inhibitor neuroserpin exacerbates ischemic brain injury by increased postischemic inflammation |
| Q33769511 | Deficiency of vasodilator-stimulated phosphoprotein (VASP) increases blood-brain-barrier damage and edema formation after ischemic stroke in mice |
| Q33318585 | Detrimental effects of tropisetron on permanent ischemic stroke in the rat. |
| Q48793530 | Does acute behavioral testing reflect successful ischemia in rats with transient middle cerebral artery occlusion? |
| Q38215496 | Does aerobic exercise training promote changes in structural and biomechanical properties of the tendons in experimental animals? A systematic review |
| Q26995520 | Effect of endothelin receptor antagonists on clinically relevant outcomes after experimental subarachnoid hemorrhage: a systematic review and meta-analysis |
| Q55081936 | Effect of laser Doppler flowmetry and occlusion time on outcome variability and mortality in rat middle cerebral artery occlusion: inconclusive results. |
| Q36382301 | Effects of the combined treatment of bone marrow stromal cells with mild exercise and thyroid hormone on brain damage and apoptosis in a mouse focal cerebral ischemia model |
| Q33369567 | Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway |
| Q30490127 | Evaluation of animal models of neurobehavioral disorders |
| Q36275582 | Evolution of ischemic damage and behavioural deficit over 6 months after MCAo in the rat: Selecting the optimal outcomes and statistical power for multi-centre preclinical trials |
| Q24288660 | Examining the Predictive Validity of NIH Peer Review Scores |
| Q35534164 | Experimental intracerebral hemorrhage: avoiding pitfalls in translational research |
| Q30771799 | Experimental models of brain ischemia: a review of techniques, magnetic resonance imaging, and investigational cell-based therapies |
| Q36497042 | Experimental models, neurovascular mechanisms and translational issues in stroke research |
| Q37157844 | Expression profiling of the cerebral ischemic and hypoxic response |
| Q34410346 | Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis |
| Q24289347 | Fighting publication bias: introducing the Negative Results section |
| Q37243686 | Good laboratory practice: preventing introduction of bias at the bench |
| Q30572344 | High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial |
| Q55322373 | Immunotherapy of experimental and human stroke with agents approved for multiple sclerosis: a systematic review. |
| Q41884542 | Impaired alpha(IIb)beta(3) integrin activation and shear-dependent thrombus formation in mice lacking phospholipase D1. |
| Q21262956 | Improving basic and translational science by accounting for litter-to-litter variation in animal models |
| Q42710506 | Improving the quality of biomedical research: guidelines for reporting experiments involving animals |
| Q51478239 | In Vitro Neuroprotective and Anti-Inflammatory Activities of Natural and Semi-Synthetic Spirosteroid Analogues. |
| Q36978960 | Inductive and Deductive Approaches to Acute Cell Injury |
| Q47172615 | Inhibition of VEGF Signaling Reduces Diabetes-Exacerbated Brain Swelling, but Not Infarct Size, in Large Cerebral Infarction in Mice |
| Q37149764 | Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review. |
| Q43189513 | International, multicenter randomized preclinical trials in translational stroke research: it's time to act. |
| Q37430180 | Ischemia-induced cell depolarization: does the hyperpolarization-activated cation channel HCN2 affect the outcome after stroke in mice? |
| Q36242265 | Lateral Chronic Cranial Window Preparation Enables In Vivo Observation Following Distal Middle Cerebral Artery Occlusion in Mice |
| Q48226147 | Levetiracetam in patients with central neuropathic post-stroke pain--a randomized, double-blind, placebo-controlled trial |
| Q42008306 | Lickometry: A novel and sensitive method for assessing functional deficits in rats after stroke. |
| Q90050344 | Light-Emitting Diode Photobiomodulation After Cerebral Ischemia |
| Q37194081 | Mesenchymal stem cells in the treatment of ischemic stroke: progress and possibilities |
| Q36579398 | Method parameters' impact on mortality and variability in mouse stroke experiments: a meta-analysis |
| Q42124955 | Methodological quality of preclinical stroke studies is not required for publication in high-impact journals |
| Q41985276 | Microelectrode Guided Implantation of Electrodes into the Subthalamic Nucleus of Rats for Long-term Deep Brain Stimulation. |
| Q38588389 | Modeling stroke in mice - middle cerebral artery occlusion with the filament model |
| Q46556319 | Moving Rehabilitation Research Forward: Developing Consensus Statements for Rehabilitation and Recovery Research. |
| Q47624954 | Moving rehabilitation research forward: Developing consensus statements for rehabilitation and recovery research |
| Q36088159 | Multi-site laser Doppler flowmetry for assessing collateral flow in experimental ischemic stroke: Validation of outcome prediction with acute MRI. |
| Q64250492 | Mural cell-derived laminin-α5 plays a detrimental role in ischemic stroke |
| Q39496194 | NADPH Oxidase as a Therapeutic Target for Neuroprotection against Ischaemic Stroke: Future Perspectives. |
| Q38197365 | Neonatal encephalopathy: pre-clinical studies in neuroprotection |
| Q36922560 | Neuroprotection and stroke: time for a compromise |
| Q24645185 | Neuroprotection for ischemic stroke: past, present and future |
| Q26866006 | New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs |
| Q80761839 | Nitrite does not provide additional protection to thrombolysis in a rat model of stroke with delayed reperfusion |
| Q26859430 | Nonhuman primate models of stroke for translational neuroprotection research |
| Q28079392 | Nonsurgical therapy for hydrocephalus: a comprehensive and critical review |
| Q33636930 | Optimizing the success of cell transplantation therapy for stroke |
| Q39860443 | Outcome of experimental stroke in C57Bl/6 and Sv/129 mice assessed by multimodal ultra-high field MRI. |
| Q26852796 | Oxidative Stress and the Use of Antioxidants in Stroke |
| Q38044931 | Pathobiology of injury after stroke: the neurovascular unit and beyond |
| Q34417107 | Peri-infarct flow transients predict outcome in rat focal brain ischemia. |
| Q36540313 | Post-stroke inflammation and the potential efficacy of novel stem cell therapies: focus on amnion epithelial cells |
| Q27323209 | Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration |
| Q92999035 | Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke |
| Q41995198 | Preclinical randomized controlled multicenter trials (pRCT) in stroke research: a new and valid approach to improve translation? |
| Q37045435 | Preclinical stroke research: gains and gaps |
| Q37574428 | Progesterone as a neuroprotective factor in traumatic and ischemic brain injury |
| Q49120809 | Protective conditioning of the brain: expressway or roadblock? |
| Q56969005 | Quality Control and Standard Operating Procedures |
| Q35451583 | Quantifying the behavioural relevance of hippocampal neurogenesis |
| Q33765349 | RODENT STROKE MODEL GUIDELINES FOR PRECLINICAL STROKE TRIALS (1ST EDITION). |
| Q48409685 | Reliability of infarct volumetry: Its relevance and the improvement by a software-assisted approach |
| Q37271448 | Reprint: Good laboratory practice: preventing introduction of bias at the bench |
| Q48731069 | Reprint: Good laboratory practice: preventing introduction of bias at the bench |
| Q41511386 | Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia. |
| Q33647103 | Rodent models of focal cerebral ischemia: procedural pitfalls and translational problems |
| Q55378901 | Scientific productivity: An exploratory study of metrics and incentives. |
| Q30642123 | Six-month ischemic mice show sensorimotor and cognitive deficits associated with brain atrophy and axonal disorganization |
| Q38170045 | Smooth muscle cell phenotypic switching in stroke. |
| Q38210235 | Spreading depolarization in the ischemic brain: does aging have an impact? |
| Q56969017 | Statistics in Experimental Stroke Research: From Sample Size Calculation to Data Description and Significance Testing |
| Q37669178 | Statistics in experimental cerebrovascular research-comparison of two groups with a continuous outcome variable |
| Q33957236 | Stem cells for ischemic brain injury: a critical review |
| Q37867782 | Stroke and the immune system: from pathophysiology to new therapeutic strategies |
| Q37346523 | Stroke research at a road block: the streets from adversity should be paved with meta-analysis and good laboratory practice |
| Q47662775 | Stroke-induced chronic systolic dysfunction driven by sympathetic overactivity. |
| Q33869531 | Sustained reperfusion after blockade of glycoprotein-receptor-Ib in focal cerebral ischemia: an MRI study at 17.6 Tesla |
| Q35588483 | Systematic review and meta-analysis of efficacy of mesenchymal stem cells on locomotor recovery in animal models of traumatic brain injury. |
| Q24289348 | Systematic survey of the design, statistical analysis, and reporting of studies published in the 2008 volume of the Journal of Cerebral Blood Flow and Metabolism |
| Q36112519 | The 1027th target candidate in stroke: Will NADPH oxidase hold up? |
| Q37701718 | The Continued Promise of Neuroprotection for Acute Stroke Treatment |
| Q30482557 | The calcium sensor STIM1 is an essential mediator of arterial thrombosis and ischemic brain infarction |
| Q48056831 | The choroid plexus is a key cerebral invasion route for T cells after stroke. |
| Q34493876 | The flaws and human harms of animal experimentation |
| Q36350527 | The indirect NMDAR antagonist acamprosate induces postischemic neurologic recovery associated with sustained neuroprotection and neuroregeneration. |
| Q37357487 | The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic. |
| Q38770603 | The next step in translational research: lessons learned from the first preclinical randomized controlled trial |
| Q38061412 | The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis |
| Q34954361 | The role of microglia and myeloid immune cells in acute cerebral ischemia |
| Q46798956 | The selective oestrogen receptor modulator, LY362321, is not neuroprotective in a rat model of transient focal ischaemia. |
| Q42414199 | The site of embolization related to infarct size, oedema and clinical outcome in a rat stroke model - further translational stroke research |
| Q37232035 | Therapeutic hypothermia in experimental models of focal and global cerebral ischemia and intracerebral hemorrhage |
| Q33640335 | Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke |
| Q34854026 | Towards a dynamical network view of brain ischemia and reperfusion. Part I: background and preliminaries |
| Q34521616 | Towards a dynamical network view of brain ischemia and reperfusion. Part III: therapeutic implications |
| Q37868574 | Translating promising preclinical neuroprotective therapies to human stroke trials |
| Q36030687 | Translational intracerebral hemorrhage: a need for transparent descriptions of fresh tissue sampling and preclinical model quality |
| Q36705446 | Translational research in stroke: taking advances in the pathophysiology and treatment of stroke from the experimental setting to clinical trials. |
| Q34743687 | Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice |
| Q34031140 | Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9). |
| Q29615508 | Update of the stroke therapy academic industry roundtable preclinical recommendations |
| Q33525255 | Use of magnetic resonance imaging to predict outcome after stroke: a review of experimental and clinical evidence |
| Q46767725 | White matter vulnerability to ischemic injury increases with age because of enhanced excitotoxicity. |
| Q89253978 | [Direct oral anticoagulants and acute stroke : Insights into translational research studies] |
| Q87383564 | [Experimental therapy approaches for ischemic stroke] |
| Q35524034 | α(2)-adrenoceptors do not mediate neuroprotection in acute ischemic stroke in mice |
Search more.